Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved Bristol-Myers Squibb's blood-thinning drug Plavix as a new option for patients with the most severe type of heart attack.
Subscribe to our email newsletter
The FDA approved the use of Plavix, which Bristol-Myers Squibb produces in partnership with Sanofi-Aventis, to reduce the risk of death from any cause and the risk of a combined endpoint of recurrent heart attack, stroke or death in patients with acute ST-elevation myocardial infarction (STEMI) – the most severe type of heart attack.
Commenting on the FDA decision, Dr Steven Steinhubl from the University of Kentucky said: “The new Plavix indication is an important milestone for patients diagnosed with acute coronary syndrome, which includes heart-related chest pain or any type of heart attack, no matter how severe.”
According to the makers of Plavix, each year more than 300,000 Americans suffer a severe type of heart attack – also known as a STEMI event. STEMI is a heart attack in which an artery is generally blocked completely and patients who have experienced STEMI and survive are at high risk of having another heart attack, a stroke or even dying.